ACADIA Pharmaceuticals Inc.
Every calculator, already run for ACAD
Open the full toolkit →You have the numbers on ACAD. Get the argument.
A written report on which of these readings actually decide the outcome for ACADIA Pharmaceuticals Inc., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
20 analysts covering ACADAnalyst Price Target Disagreement for ACADIA Pharmaceuticals Inc.
Wall Street's bull case implies +80% from the current price; the bear case implies -38%. A 117% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
Insider Trading Activity for ACAD
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America. The company offers NUPLAZID (pimavanserin), a selective serotonin inverse agonist/antagonist for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 to treat the symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function. It also develops remlifanserin, which is in phase 2 clinical trial for the treatment of alzheimer's disease psychosis and lewy body d…
ACAD — frequently asked
Is ACAD a buy right now?
Wall Street's consensus rating on ACADIA Pharmaceuticals Inc. is Buy across 20 analysts, with a mean price target of $33.89 (+24% vs. the current $27.29). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
Is ACAD overvalued?
ACAD trades at 12.2x trailing earnings, against a DCF fair value of $9 per share. The current price implies 21% annual free-cash-flow growth for a decade. Open the DCF or reverse-DCF tool to change the assumptions and see the range.
When is ACAD's next earnings date?
ACADIA Pharmaceuticals Inc. is next scheduled to report earnings around Nov 4, 2026. A full ACAD research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for ACADIA Pharmaceuticals Inc.?
Analysts covering ACADIA Pharmaceuticals Inc. (ACAD) range from a bear-case target of $17.00 to a bull-case high of $49.00, with a mean consensus target of $33.89 across 19 analysts. The spread of $32.00 (117% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare ACADIA Pharmaceuticals Inc. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For ACADIA Pharmaceuticals Inc.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full ACAD research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on ACADIA Pharmaceuticals Inc., in minutes. 3 free reports included with every account — no credit card required.